Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Pharmaceuticals Revenues Up for Fourth Quarter, Year

NEW YORK, February 12 -- Genaissance Pharmaceuticals of New Haven, Conn., today announced increased revenues for the fourth quarter, ending Dec. 31, 2002, and for the year.

 

The company reported revenues of $2.6 million, compared to $2.2 million for the fourth quarter of 2001, and $8.1 million for the year, compared to $5.3 million for the same period a year ago.

 

The company had a net loss of $5.6 million for the quarter, compared to a loss of $11.4 million for the fourth quarter of 2001, and $33.3 million for the year, compared to $47.6 million for 2001.

 

The company reported cash, cash equivalents and securities totaling $34.2 million.

 

Genaissance restructed in the third quarter 2002, laying off 20 percent of its workforce.   Kevin Rakin, former president and CFO of Genaissance, replaced Gualberto Ruano, a company founder and its CEO since its inception in 1997. In the meantime, the company was able to avoid delisting on the Nasdaq exchange.   

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.